ClinicalTrials.gg
RecruitingNCT05146726Updated Jul 2, 2025

Patient Blood Management Charité (PBM-Charité): Structured Detection, Differentiated Diagnostics and Therapy of Preoperative Anemia and Use of Machine Autotransfusion in Elective Interventions

An observational study in Anemia, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Anemia with a site in Germany — 14 open to participants now, 27 under way, 14 of them phase 3. Anemia · Germany.

Planned enrollment
6th of 31
2,700 · median 800
Started
2022
with 9 others
Observational
31 of 151
8 open now
Primary completion
2027-02
later than 12 of 26 live
Registered
129th of 151
by date

Among the 151 studies in Anemia with a site in Germany, this one is the 6th largest by planned enrollment of the 31 observational ones that give a count, is one of 10 that started in 2022, is one of 31 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 129th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

14 of the 151 studies in Anemia with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Anemia with a site in Germany, or all of them as a file.
02

Study summary

The aim of patient blood management is to reduce the risks of perioperative anemia- and transfusion-associated complications by limiting the use and the need for allogeneic blood transfusion.

Read the detailed description

Background of this multimodal, multidisciplinary concept are numerous studies that have shown an association between preoperative anemia and/or a perioperative transfusion and a worse treatment outcome concerning morbidity and mortality. Diagnosis and therapy of preoperative anemia and the use of machine autotransfusion are central components of this integrated supply concept based on the S3 guideline "Präoperative Anämie", which need to be incorporated into the clinical processes.

Therefore, all patients undergoing elective surgery with a probability of transfusion > 10% receive an anemia detection during their premedication visit. Patients who are insured with BARMER also get anemia diagnostic and therapy. Patients of other health insurances receive a recommendation to anemia diagnostics and therapy sent to surgical department. Based on an analysis of the primary and secondary endpoints of this prospective cohort study, the implementation of the mentioned guideline-compliant measures in everyday clinical practice and the effectiveness of an IV-PBM (Patient blood management) are to be examined. Thus, if necessary, other health insurances could join the patient blood management (PBM) IV concept. The aim is to provide evidence of an improved quality of treatment and the generalized application of PBM measures within the scope of the innovative PBM care form described.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Transfusion
  • Machine autotransfusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with preoperative anemia and an electivesurgical intervention with a probability of transfusion > 10%

Eligibility criteria

Prospective:

Inclusion Criteria:

  • age ≥ 18 years
  • male and female patients
  • patients eligible for inclusion: by the patient, preoperatively
  • patients who are insured with BARMER
  • patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10%

additionally for the use of MAT:

  • indication of machine autotransfusion
  • high blood loss (> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)

Exclusion Criteria:

  • patients with emergency interventions
  • rejection of study participation
  • pregnancy, elective caesarean section or breastfeeding
  • not enough German language skills
  • accommodation in an institution because of judicial or administrative order
  • employee of Charité
  • missing of declaration of consent

Retrospective:

Inclusion Criteria:

-Data since September 2021-February 2024 of patients who are not insured with BARMER with elective (N5) interventions with a transfusion probability > 10% (indication list) with a preoperatively existing anemia

additionally for the use of MAT:

  • indication of machine autotransfusion
  • high blood loss (> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual platelet inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective BARMER insured patients

    Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10%. Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service).

    Other: BARMER anemia treatment

  • Retrospective patients insured with another statutory health insurer than BARMER

    Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10% and receive early anemia detection.

    Other: NON-BARMER anemia treatment

Interventions

  • OtherBARMER anemia treatment

    BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.

  • OtherNON-BARMER anemia treatment

    Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)

06

What researchers measure

Primary outcomes

  1. Number of patients

    The amount of patients with differential diagnostics and causally appropriate therapy of a preoperative anemia of all patients with preoperative anemia before an elective surgical intervention with a probability of transfusion \> 10% at study completion date = third year after start date (implementation rate of therapy recommendation). Approximately 9600 patients will be enrolled in the study. The data is evaluated after 3 years.

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

Secondary outcomes

  1. Number of patients

    The amount of patients with differential diagnostics and causally appropriate therapy of a preoperative anemia of all patients with preoperative anemia before an elective surgical intervention with a probability of transfusion \> 10% after the first and second year after start date (implementation rate of therapy). The data of 2 is evaluated after 1 year and 2 years.

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  2. Number of machine autotransfusion respectively autologous transfusion

    Number of patients which received machine autotransfusion

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  3. Rate of transfused patients

    Number of patients which received transfusions

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  4. ∆Hb before therapy of anemia and before surgical intervention

    Difference between Hemoglobin before therapy of anemia and Hemoglobin before surgical intervention.

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  5. Number of allogeneic transfusions

    Number of red cell concentrates per patient

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  6. Treatment period

    Treatment period between begin of anemia therapy and surgical intervention

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  7. Treatment dose of anemia therapeutics in relation to ∆Hemoglobin

    Treatment dose of anemia therapeutics in relation to the difference between Hemoglobin before begin of anemia therapy and the Hemoglobin before surgical intervention

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  8. Side effects 1

    Side effects of anemia therapeutics

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  9. Side effects 1

    Type of side effects of anemia therapeutics

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  10. Differences of secondary outcome measures

    Differences of secondary outcome measures 2. - 10. mentioned above between long term and short term treatment (anemia therapy, long term treatment \>3 weeks preoperative, short term treatment 1 - 3 days preoperative).

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  11. Anemia course

    Change of Hemoglobin during hospital stay until hospital discharge

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  12. Length of hospital stay

    Length of stay at the hospital

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  13. Length of intensive care unit stay

    Length of stay at the intensive care unit

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 3 days

  14. Rate and type of postoperative complications

    Rate and type of Organ complications which are documented in the hospital records.

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  15. Side effects 2

    Type of side effects of machine autotransfusion

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  16. Rate of side effects

    Rate of side effects of machine autotransfusion

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  17. Volumes of collected blood

    Volumes of collected blood from Machine autotransfusion

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  18. Retransfused blood

    Retransfused blood from Machine autotransfusion

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  19. Quality indicator 1

    Quality indicators for machine autotransfusion as process time

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  20. Quality indicator 2

    Quality indicators for machine autotransfusion as operating time

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  21. Quality indicator 3

    Quality indicators for machine autotransfusion as number of washing processes

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  22. Quality indicator 4

    Quality indicators for machine autotransfusion as surgery department

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  23. Quality indicator 5

    Quality indicators for machine autotransfusion as patient population

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

  24. Rate of In-hospital mortality

    Mortality is measured during hospital stay

    Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité - University Medicine Berlin
    Berlin, 13353, Germany
    Recruiting
    • Claudia Spies, MD, Prof. · Contactclaudia.spies@charite.de · +49 30 450 55 10 01
    • Lutz Kaufner, MD · Sub investigator
    • Franziska Büttner, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Of 124 non-industry observational studies under Anemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 83. This study's planned 60 months is above that.

Counting every sponsor, half of 145 studies reached it within 30 months; a quarter within 11 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Dec 7, 2021
StartActual
Feb 2, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05146726
Responsible party
Claudia Spies (Head of the Department of Anesthesiology and operative Intensive Care (CCM/CVK), Charité- Universitätsmedizin Berlin, Charite University, Berlin, Germany) — Principal investigator
First posted
Dec 7, 2021
Start date
Feb 2, 2022
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 2, 2025

Study contacts

Claudia Spies, MD, Prof.
Contact
claudia.spies@charite.de
+49 30 450 55 11 02
Claudia Spies, MD, Prof.
study director · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion